| __timestamp | Lantheus Holdings, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 176081000 | 570979 |
| Thursday, January 1, 2015 | 157939000 | 2185000 |
| Friday, January 1, 2016 | 164073000 | 4554000 |
| Sunday, January 1, 2017 | 169243000 | 3605000 |
| Monday, January 1, 2018 | 168489000 | 5527000 |
| Tuesday, January 1, 2019 | 172526000 | 5234000 |
| Wednesday, January 1, 2020 | 200649000 | 6126000 |
| Friday, January 1, 2021 | 237513000 | 6784000 |
| Saturday, January 1, 2022 | 353358000 | 7592000 |
| Sunday, January 1, 2023 | 586886000 | 11450000 |
Cracking the code
In the ever-evolving landscape of biotechnology, cost efficiency remains a pivotal factor for success. This analysis delves into the cost of revenue trends for Lantheus Holdings, Inc. and Travere Therapeutics, Inc. over the past decade. From 2014 to 2023, Lantheus Holdings demonstrated a remarkable increase in cost efficiency, with their cost of revenue surging by over 230%, from approximately $176 million to $587 million. In contrast, Travere Therapeutics, while experiencing growth, maintained a more modest increase of around 1900%, from $0.57 million to $11.45 million. This stark contrast highlights Lantheus Holdings' aggressive expansion and operational scaling, while Travere Therapeutics focuses on steady growth. As the biotech industry continues to innovate, understanding these financial dynamics offers valuable insights into strategic decision-making and competitive positioning.
Novo Nordisk A/S vs Lantheus Holdings, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Travere Therapeutics, Inc.
Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Lantheus Holdings, Inc. vs MorphoSys AG
Analyzing Cost of Revenue: Lantheus Holdings, Inc. and Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Lantheus Holdings, Inc. vs Taro Pharmaceutical Industries Ltd.
Lantheus Holdings, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
ACADIA Pharmaceuticals Inc. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Vericel Corporation vs Travere Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: HUTCHMED (China) Limited vs Travere Therapeutics, Inc.
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.
Cost Insights: Breaking Down Travere Therapeutics, Inc. and Dyne Therapeutics, Inc.'s Expenses